Amylyx Pharmaceuticals (AMLX) Insider Trading & Ownership $4.05 +0.09 (+2.27%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.70%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$326,397.50Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$494,508.16 Get AMLX Insider Trade Alerts Want to know when executives and insiders are buying or selling Amylyx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AMLX Insider Buying and Selling by Quarter Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Amylyx Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/30/2024Camille L BedrosianInsiderSell11,442$3.20$36,614.40 9/30/2024Justin B KleeCEOSell18,589$3.20$59,484.80 9/12/2024James M FratesCFOBuy40,000$2.53$101,200.00 9/3/2024George M Milne JrDirectorBuy100,000$2.20$220,000.00 5/15/2024Gina MazzarielloInsiderSell10,455$1.88$19,655.40 5/14/2024Daphne QuimiDirectorBuy2,750$1.89$5,197.50 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/5/2024Gina MazzarielloInsiderSell1,540$18.73$28,844.20 3/5/2024James M FratesCFOSell1,792$18.73$33,564.16 3/5/2024Joshua B CohenCEOSell4,135$18.73$77,448.55 2/23/2024Gina MazzarielloInsiderSell2,838$18.76$53,240.88 1/9/2024James M FratesCFOSell2,716$16.33$44,352.28 1/9/2024Justin B KleeCEOSell5,841$16.33$95,383.53 1/9/2024Patrick D YeramianInsiderSell2,812$16.33$45,919.96 (Data available from 1/1/2013 forward) AMLX Insider Trading Activity - Frequently Asked Questions Who is on Amylyx Pharmaceuticals's Insider Roster? The list of insiders at Amylyx Pharmaceuticals includes Camille L Bedrosian, Daphne Quimi, George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment, and Patrick D Yeramian. Learn more on insiders at AMLX. What percentage of Amylyx Pharmaceuticals stock is owned by insiders? 11.70% of Amylyx Pharmaceuticals stock is owned by insiders. Learn more on AMLX's insider holdings. Which Amylyx Pharmaceuticals insiders have been buying company stock? The following insiders have purchased AMLX shares in the last 24 months: Daphne Quimi ($5,197.50), George M Milne Jr ($220,000.00), and James M Frates ($101,200.00). How much insider buying is happening at Amylyx Pharmaceuticals? Insiders have purchased a total of 142,750 AMLX shares in the last 24 months for a total of $326,397.50 bought. Which Amylyx Pharmaceuticals insiders have been selling company stock? The following insiders have sold AMLX shares in the last 24 months: Camille L Bedrosian ($36,614.40), George M Milne Jr ($1,116,150.00), Gina Mazzariello ($225,421.62), James M Frates ($1,989,891.44), Joshua B Cohen ($77,448.55), Justin B Klee ($3,340,868.33), Morningside Venture Investment ($10,931,921.94), and Patrick D Yeramian ($3,648,369.06). How much insider selling is happening at Amylyx Pharmaceuticals? Insiders have sold a total of 715,213 Amylyx Pharmaceuticals shares in the last 24 months for a total of $21,366,685.34 sold. Amylyx Pharmaceuticals Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Compensation: $1.08MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Compensation: $1.08M1 recent tradesMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Compensation: $763.16k1 recent tradesMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Compensation: $689.26kDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Compensation: $232.6k1 recent tradesMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GM More Insider Trading Tools from MarketBeat Related Companies RCKT Insider Ownership BCYC Insider Ownership AVDL Insider Ownership SEPN Insider Ownership COLL Insider Ownership ZYME Insider Ownership BCAX Insider Ownership GYRE Insider Ownership PSTX Insider Ownership COGT Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:AMLX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
